Claro Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Claro Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5,134	Closed	-$575K	–	328
2022 Q1	$575K	Hold	5,134	–	–	0.21%	133
2021 Q4	$575K	Buy	5,134 +22	+0.4%	+$2.65K	0.21%	133
2021 Q3	$643K	Buy	5,112 +306	+6%	+$39.4K	0.27%	105
2021 Q2	$651K	Buy	4,806 +657	+16%	+$86.4K	0.29%	94
2021 Q1	$563K	Buy	+4,149	New	+$621K	0.29%	94

Other funds holding XBI

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Claro Advisors's XBI Position: Q2 2022 in Review

Claro Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2022, closing a stake of 5,134 shares — an estimated $575K sold.

Claro Advisors first reported a position in XBI in Q1 2021 and held it in 5 quarters. The position peaked at $651K in Q2 2021. 704 funds tracked by Wall St. Rank hold XBI as of Q2 2022.

Claro Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2022 after selling out during the quarter.
Claro Advisors sold 5,134 State Street SPDR S&P Biotech ETF shares in Q2 2022, an estimated $575K.
Claro Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q1 2021 and held it in 5 quarters.
Claro Advisors's State Street SPDR S&P Biotech ETF position peaked at $651K in Q2 2021.
704 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2022.

Based on Claro Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.